NCT02068339View on ClinicalTrials.gov

Efficacy and Safety of Oltipraz for Liver Fat Reduction in Patients With Non-Alcoholic Fatty Liver Disease Except for Liver Cirrhosis

PHASE3CompletedINTERVENTIONAL
Enrollment

283

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

February 29, 2016

Study Completion Date

March 31, 2016

Conditions
Non-alcholic Fatty Liver Disease
Interventions
DRUG

Oltipraz 1 (90mg)

DRUG

Placebo

DRUG

Oltipraz 2 (120mg)

Trial Locations (5)

410-719

NHUS Ilsan Hospital, Ilsan-ro Ilsan-donggu

411-706

Inje University Ilsan Paik Hospital, Dahwa-dong, Ilsanseo-gu, Goyang-si

110-744

Seoul National University Hospital, Daehak-ro Jongno-gu

152-703

Korea University Guro hospital, Gurodong-ro

156-707

Boramae Hospital, Sindaebang-dong Dongjak-gu

Sponsors

Lead Sponsor

PharmaKing
All Listed Sponsors
lead

PharmaKing

INDUSTRY